Windward Bio Group (WWB): Windward Bio Surges 68% in Strong Biotech IPO Debut
Windward Bio Group’s (WWB US) debut gave the biotech IPO market a welcome burst of momentum. Shares of the clinical-stage company priced at $17.00, the midpoint of the marketed range, and opened at $18.35 for a 7.9% gain. Buying accelerated quickly: the stock rose roughly six points within its first 15 minutes, reached an intraday high of $33.99 by 3 p.m. ET, and closed at $28.50. That left WWB up 67.6% from its IPO price at the close, after briefly doubling. The day one close performance was the fourth best by an IPO in 2026 by percentage behind Veradermics, Hemab Therapeutics and Cerebras Systems Inc..
The offering finished multiple times oversubscribed, with strong participation from long-only and healthcare-dedicated investors. That institutional demand helped support a well-received launch and stands out in a biotech IPO market where investor appetite has varied sharply from deal to deal.
As we often observe, biotech offerings can be “highly clubby,” with a large share of public allocations often going to existing investors. During IPO lulls, the sector may also be less directly affected by broader market conditions: chunky orders and smaller deal sizes can make offerings more manageable. WWB’s first-day surge demonstrates that investor demand is available for select stories.
VVardis Holding AG (VVVV): A Painful IPO Debut for VVARDIS as Shares Fall Below Issue
For vVARDIS Holding (VVVV US), the market’s first look at its drill-free cavity treatment was a painful one. The Swiss dental technology company priced 9.72 million shares at $18—$3 below the $21–$24 range—and VVVV opened at $14, a 22.2% drop from the IPO price. The shares later started to recover, but the rebound did not erase a debut that showed how little appetite investors had for the deal’s valuation and last-minute restructuring.
The final deal followed a volatile week of changes. vVARDIS first reduced the proposed offering to 8.33 million shares, then increased it to 9.72 million at pricing. The company also removed the secondary component and lowered the price to $18, adding primary shares as it sought to maintain its targeted cash raise. The final offering raised approximately $175 million gross.
VVVV’s $14 opening print was also its low for the session. Shares climbed to an intraday high of $16.94 and closed at $16.50. That was a 17.9% recovery from the open, but the stock still finished 8.3% below its $18 IPO price. The offering economics saw the top five accounts take 65% of the deal and top 10 took 85%.
vVARDIS may still have an important innovation in dental care, and its revenue growth gives investors a reason to watch the company beyond its debut. But the first day made clear that a promising treatment alone was not enough to support the proposed valuation.
Rezera (RZRA US) postponed its IPO due to market conditions, shelving a planned Thursday, November 12 debut. The biotech had sought to sell 16.7 million shares at $11–$13, targeting a roughly $200 million raise at the midpoint. Even with a modest deal by IPO standards, a steep discount to its July financing and up to $25 million in nonbinding interest from GSK, Rezera could not bring the offering to market.
Looking ahead to next week, Anthropic’s highly anticipated IPO is on deck. The company is looking to challenge Elon Musk’s SpaceX (SPCX) IPO for largest cash raise in history. As a landmark AI-sector listing, it will be a critical test of public-market appetite for the industry’s growth.
